CoChat

Estrogen Deficiency and the Origin of Obesity during Menopause

Open access
Lizcano, Fernando, Guzmán, Guillermo · 2014 · BioMed Research International

The DOI matches its Crossref record; 172 of the 172 references it cites were found in a registry or an index; 16 of the 142 sources its claims cite were checked for support.

Abstract

Sex hormones strongly influence body fat distribution and adipocyte differentiation. Estrogens and testosterone differentially affect adipocyte physiology, but the importance of estrogens in the development of metabolic diseases during menopause is disputed. Estrogens and estrogen receptors regulate various aspects of glucose and lipid metabolism. Disturbances of this metabolic signal lead to the development of metabolic syndrome and a higher cardiovascular risk in women. The absence of estrogens is a clue factor in the onset of cardiovascular disease during the menopausal period, which is characterized by lipid profile variations and predominant abdominal fat accumulation. However, influence of the absence of these hormones and its relationship to higher obesity in women during menopause are not clear. This systematic review discusses of the role of estrogens and estrogen receptors in adipocyte differentiation, and its control by the central nervous systemn and the possible role of estrogen-like compounds and endocrine disruptors chemicals are discussed. Finally, the interaction between the decrease in estrogen secretion and the prevalence of obesity in menopausal women is examined. We will consider if the absence of estrogens have a significant effect of obesity in menopausal women.

Overview

CoChat Summary

TL;DR

This systematic review examines whether estrogen deficiency contributes to obesity during menopause, covering estrogen receptors, adipocyte biology, central appetite regulation, adipokines, endocrine disruptors, and hormone therapy. It concludes that estrogen loss is linked to abdominal fat accumulation and metabolic risk, but causality and optimal hormone therapy remain unclear.

Key findings

  • Estrogen deficiency after menopause is associated with loss of subcutaneous fat and an increase in abdominal fat; obesity prevalence in American women reaches 65% between ages 40–59 and 73.8% over age 60, and menopausal women are three times more likely to develop obesity and metabolic syndrome abnormalities than premenopausal women.
  • Estrogen receptors, especially ERα, mediate metabolic effects: female and male mice lacking ERα have central obesity, severe insulin resistance, and diabetes; E2 administered to ovariectomized mice on a high-fat diet improved glucose tolerance and insulin sensitivity in wild-type but not ERα−/− mice.
  • Estrogens influence appetite and energy regulation: they inhibit orexigenic NPY and MCH effects, deletion of ER in POMC neurons in mice leads to hyperphagia without directly influencing energy expenditure or adipose tissue distribution, and ovariectomized rats regain normal weight after estrogen replacement.
  • Hormone therapy findings are mixed: a meta-analysis of over 100 randomized trials in menopausal women concluded that oral and transdermal estrogen, with or without progestin, increases lean body mass, reduces abdominal fat, improves insulin resistance, decreases LDL/HDL cholesterol ratio, and decreases blood pressure in women without diabetes; WHI DXA at six-year follow-up showed decreased loss of body fat mass with hormonal therapy in the first three years but not after six years.

Methods

  • The study design was a review of existing published original papers and reviews, conducted in accordance with the PRISMA statement.
  • PubMed publications until Nov 30, 2013, were taken into account.
  • No primary data collection or quantitative meta-analysis is reported; the synthesis is narrative across animal and human studies.

Limitations

  • The paper states that the influence of estrogen absence and its relationship to higher obesity in menopausal women are not clear, that reasons for increasing obesity in menopausal women are not clear, and that triggers for obesity require further investigation; it also states that further studies are required to clarify endocrine disruptor involvement and that stringent studies in different locations are essential.
  • The paper states that hormone therapy during menopause will always be a mixed picture of benefits and risks, requiring individual assessment of needs and potential risks.
  • Evident from the text: as a review, it does not report a formal quantitative synthesis, risk-of-bias assessment, or detailed inclusion/exclusion criteria, and it draws on heterogeneous animal models and human studies, limiting causal conclusions.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1155/2014/757461

Cites

172 of 172 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Estrogen in the fat cell. (a) In brown adipocyte cell the ER alpha receptor can increase the expression of UCP1 by increasing PGC1alpha coactivator through AMPk and by a direct effect on the receptor coactivator. (b) In white adipocyte ER alpha receptor activation by estrogen reduces lipoprotein lipase and increases beta-adrenergic receptor activity. UCP1: uncoupling protein 1; PGC1alpha: peroxisome proliferative activated receptor gamma coactivator 1 alpha; ER: estrogen receptor; AMPk: AMP-activated protein kinase. LPL: lipoprotein lipase; β-AR: adrenergic receptor beta.
Figure 1 Estrogen in the fat cell. (a) In brown adipocyte cell the ER alpha receptor can increase the expression of UCP1 by increasing PGC1alpha coactivator through AMPk and by a direct effect on the receptor coactivator. (b) In white adipocyte ER alpha receptor activation by estrogen reduces lipoprotein lipase and increases beta-adrenergic receptor activity. UCP1: uncoupling protein 1; PGC1alpha: peroxisome proliferative activated receptor gamma coactivator 1 alpha; ER: estrogen receptor; AMPk: AMP-activated protein kinase. LPL: lipoprotein lipase; β-AR: adrenergic receptor beta.CC BY · PubMed Central
Figure 2 Estrogen hypothalamic control of obesity. ER alpha in the brain regulates body weight in both males and females ▸ ER alpha in female SF1 neurons regulates energy expenditure and fat distribution ▸ ER alpha in female POMC neurons regulates food intake. POMC: proopiomelanocortin; SF1: steroidogenic factor-1.
Figure 2 Estrogen hypothalamic control of obesity. ER alpha in the brain regulates body weight in both males and females ▸ ER alpha in female SF1 neurons regulates energy expenditure and fat distribution ▸ ER alpha in female POMC neurons regulates food intake. POMC: proopiomelanocortin; SF1: steroidogenic factor-1.CC BY · PubMed Central
Figure 3 Estradiol availability affects the regulation of enzymes involved in tricarboxylic acid cycle activity. E2 enhances the glycolytic/pyruvate/acetyl-CoA pathway to generate electrons required for oxidative phosphorylation and ATP generation to sustain utilization of glucose as the primary fuel source.
Figure 3 Estradiol availability affects the regulation of enzymes involved in tricarboxylic acid cycle activity. E2 enhances the glycolytic/pyruvate/acetyl-CoA pathway to generate electrons required for oxidative phosphorylation and ATP generation to sustain utilization of glucose as the primary fuel source.CC BY · PubMed Central
Figure 4 Components with estrogens effects. Estrogen and some endocrine disruptors that have an estrogenic effect. DDT is a chemical fertilizer. Bisphenol A is an organic compound used to make polycarbonate polymers and epoxy resins; Genistein is an isoflavone found in a number of plants including soy. DDT: dichlorodiphenyltrichloroethane.
Figure 4 Components with estrogens effects. Estrogen and some endocrine disruptors that have an estrogenic effect. DDT is a chemical fertilizer. Bisphenol A is an organic compound used to make polycarbonate polymers and epoxy resins; Genistein is an isoflavone found in a number of plants including soy. DDT: dichlorodiphenyltrichloroethane.CC BY · PubMed Central

Verification

Claims the paper makes

8 Valid · 2 Not valid · 67 Not checked · 4 Own results and interpretations

25 more claims · 1 with their cited sources checked

Create a free account to see all 81 claims and to verify the 125 references still open.

See all claims — free account
  • It may state two separate claims as one. 40
  • Probably not a substantial claim. 15

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Research works printed but not linked: 12

  1. 2012, Obesity, 20, 2183
  2. 1988, Acta Medica Scandinavica, 223, 121
  3. 2012, PLOS Genetics, 8
  4. 2002, Journal of Nutrition, Health and Aging, 6, 123
  5. 2001, American Journal of Physiology, 280, E496
  6. 1999, American Journal of Physiology, 276, E317
  7. 2001, Cell, 104, 719
  8. 2012, American Journal of Physiology, 303, E445
  9. 2013, American Journal of Physiology, 304, E1167
  10. 2013, International Journal of Obesity
  11. 2013, Journal of Clinical Endocrinology and Metabolism
  12. 1987, Neuroscience Letters, 84, 197

Cited by

See all 586

Metadata

Authors
Lizcano, F., & Guzmán, G.
Affiliations
Universidad de La Sabana (CO)
Corresponding author
Lizcano, Fernando
Venue
BioMed Research International
Published
2014
Volume
2014
Pages
1-11
ISSN
  • 1110-7243 (ISSN-L)
  • 2314-6133
  • 2314-6141
OpenAlex
W1985061586
Cited by
586
References
172
Citations by year
2026: 38 · 2025: 65 · 2024: 64 · 2023: 59 · 2022: 67 · 2021: 65 · 2020: 64 · 2019: 47 · 2018: 42 · 2017: 24 · 2016: 27 · 2015: 19 · 2014: 5
FWCI
3.90
Type
journal article
Language
en
Open access
Locations
  • BioMed Research International (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Intellectum (Universidad de La Sabana) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Keywords
estrogen deficiency, menopause, obesity, estrogen receptor, adipogenesis, body fat distribution, metabolic syndrome, cardiovascular risk, lipid profile, abdominal fat, endocrine disruptors, estrogenic compounds, sex hormones
MeSH terms
Central Nervous System, Estradiol, Estrogens, Female, Humans, Menopause, Middle Aged, Obesity, Receptors, Estrogen, Overweight, Lipid Metabolism, Adipokines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.